Several lines of studies have suggested the importance of cortical dopamine (DA) transmission in the pathophysiology of schizophrenia. The putative alteration of striatal D 2 receptor density in schizophrenia has been studied intensely, although extrastriatal DA activity may be more relevant for behavioral symptoms. The aim of this study was to explore extrastriatal D 2/3 density in drug-naive schizophrenic patients. We studied the extrastriatal D 2/3 receptor binding with a novel highaffinity single-photon emission tomography ligand epidepride in seven drug-naive schizophrenic patients and seven matched controls. The symptoms were rated with Positive and Negative Syndrome Scale for Schizophrenia. The findings indicated an extremely low D 2/3 receptor binding among patients in temporal cortex in both hemispheres when compared with controls (effect size 2.0-2.3), and the D 2/3 levels had negative correlations with general psychopathological (r from À0.86 to À0.90) and negative (r from À0.37 to À0.55) schizophrenic symptoms. These results support the previous hypothesis on dysfunction of mesocortical DA function behind the cognitive and negative symptoms in schizophrenia. Molecular Psychiatry (2003Psychiatry ( ) 8, 453-455. doi:10.1038 Since the introduction of chlorpromazine in psychiatry in 1952, all antipsychotic drugs with proven efficacy have been dopamine (DA) D 2 receptor antagonists. It has been suggested that positive schizophrenic symptoms are associated with increased subcortical DA neurotransmission, and negative and cognitive symptoms with impaired mesocortical DA function.
Since the introduction of chlorpromazine in psychiatry in 1952, all antipsychotic drugs with proven efficacy have been dopamine (DA) D 2 receptor antagonists. It has been suggested that positive schizophrenic symptoms are associated with increased subcortical DA neurotransmission, and negative and cognitive symptoms with impaired mesocortical DA function. 1 Studies on striatal D 2 receptor densities in drug-naive schizophrenic patients have indicated that deviation in D 2 density is larger among patients vs controls, and although some patients have markedly elevated D 2 levels, the D 2 densities do not differ substantially at the group level. [2] [3] [4] Although DA neurotransmission in the basal ganglia may be more important for motor functions rather than for emotions and behavioral symptoms, D 2 binding studies have previously concentrated in the striatum, because there have been no suitable in vivo ligands available for measuring extrastriatal D 2 receptor binding. Recent studies with novel PET, that is single-photon-emission tomography (SPET) ligands have shown D 2 receptor binding in all cortical areas, but the highest binding has been observed in the temporal cortex. 5 Recently, the first in vivo study on extrastriatal D 2 receptor binding among drug-naive schizophrenic patients revealed decreased D 2/3 receptor density in the anterior cingulate cortex. 6 The aim of this study was to test the hypothesis that extrastriatal D 2/3 density in the temporal and cingulate cortex is lower among drug-naive schizophrenic patients when compared with matched controls.
The distribution of epidepride binding among schizophrenic patients and healthy controls is shown in Figure 1 . The greatest cortical binding was observed in temporal cortices, and there was a substantial negative correlation between age and epidepride binding among controls (r ¼ À0.77, P ¼ 0.04 on the left, r ¼ À0.71, P ¼ 0.07 on the right, Pearson's two-tailed correlation) but not among patients (r ¼ 0.11, P ¼ NS on the left, r ¼ À0.28, P ¼ NS on the right). The binding values (ml/ml; mean7SD) were lower among patients than controls in the left temporal cortex (0.7670.12 vs 1.0770.14, effect size ¼ 2.3, F ¼ 18.4, P ¼ 0.001, analysis of covariance (ANCOVA)) and in the right temporal cortex (0.7870.12 vs 1.1070.19, effect size ¼ 2.0, F ¼ 16.1, P ¼ 0.002). (The F-and P-values obtained with ANOVA without age adjustment remained almost the same: F ¼ 18.8, P ¼ 0.001 on the left, F ¼ 14.2, P ¼ 0.003 on the right.) There were substantial negative correlations (Pearson's two-tailed correlation, age adjusted) between positive and negative syndrome scale for schizophrenia (PANSS) general psychopathological score and epidepride binding (r ¼ À0.90, P ¼ 0.014 on the left; r ¼ À0.86, P ¼ 0.028 on the right). The correlations between the epidepride binding and the PANSS negative symptom score (r ¼ À0.55, P ¼ NS on the left; r ¼ À0.37, P ¼ NS on the right) and positive symptom score (r ¼ À0.08, P ¼ NS on the left, r ¼ À0.18, P ¼ NS on the right) were weaker. In both hemispheres, D 2/3 density explained a substantial proportion of the variance of the general psychopathological symptom score (r 2 ¼ 81% on the left, r 2 ¼ 74% on the right) and a somewhat smaller proportion of the variance of negative symptom score (r 2 ¼ 30% on the left, r 2 ¼ 14% on the right).
Epidepride and the [ 11 C]FLB 457 (the bromo analogue of epidepride) are the first ligands, which enable to measure the extrastriatal D 2/3 binding in vivo. The extremely high affinity of these ligands is optimal for studying the relatively low density of D 2/3 receptors in extrastriatal regions. Measuring the striatal D 2 binding reliably is very difficult, because the ligand binding does not reach equilibrium in basal ganglia, which have high D 2 receptor density. Therefore, this study focused on measuring the extrastriatal epidepride binding in the temporal cortex, and the results from the striatum were excluded. The specific binding values in the frontal cortex were less than half of those in the temporal cortex and were too low for reliable evaluation. Owing to small sample size and limited spatial resolution, we did not do any further detailed analysis on the subregions of the temporal cortex.
The results indicate that in drug-naive schizophrenic patients the extrastriatal DA D 2/3 receptor density is markedly decreased. We also observed negative correlations between D 2/3 receptor density and age among controls, and between D 2/3 density and PANSS negative and general psychopathological symptom scores among patients. These results on binding are consistent with the previous PET study, 6 although Suhara et al. observed the strongest negative correlations between the BPRS (Brief Psychiatric Rating Scale)-positive symptoms (rather than general psychopathological symptoms) and D 2/3 binding. In the PET study, the correlations were stronger for the binding in the anterior cingulate cortex than in the temporal cortex. Our results showed far stronger correlations for epidepride binding in the temporal cortex vs PANSS symptoms than the corresponding correlations (in the temporal cortex) between [ 11 C]FLB binding vs BPRS symptoms in the study by Suhara et al. We were not able to study the binding in the frontal cortex due to low specific binding in that region. Despite the relatively small sample size, our findings on patients vs controls in the temporal cortex met statistically the level of significance in both hemispheres, and in the [ 11 C]FLB study, the results showed the same tendency. 6 These results support the previous hypothesis on dysfunction of mesocortical DA function behind the cognitive and negative symptoms in schizophrenia.
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Method
The study protocol was accepted by the Kuopio University Hospital ethical committee. Seven drugnaive patients fulfilling the ICD-10 criteria for schizophrenia participated in the study (four females) aged 19-51 years, mean 31.9 (SD ¼ 13.9). The diagnoses were verified with Structured Clinical Interview for DSM-III-R (SCID) (by HT). The duration of illness ranged from 1 month to 3 years (mean 1.2 years). Coexisting substance abuse and neuropsychiatric disorders were the exclusion criteria, and magnetic resonance imaging (MRI) was performed to detect possible traumas and neuroanatomical anomalies. The schizophrenic symptoms of the patients were rated with PANSS (by HT), and the mean scores were 88.71 (SD ¼ 18.03) for total, 23.43 (SD ¼ 6.08) for positive, 21.86 (SD ¼ 6.82) for negative, and 43.43 (SD ¼ 8.68) for general psychopathological score. Seven healthy control subjects (three females) were aged between 20-42 years, mean 31.4 (SD ¼ 8.7). Written, informed consent was obtained from all subjects after complete description of the study. . The MRI scans demonstrate the level of the summed SPET slices. The highest ligand uptake is seen in temporal lobes. Note the low uptake in patients compared with controls. On the right, the scatter plot demonstrates the epidepride binding in the left (triangles) and the right (inverted triangles) temporal lobes in controls (n ¼ 7) and patients (n ¼ 7).
[ 123 I]epidepride (185 MBq; supplied by MAP Medical Technologies Oy, Tikkakoski, Finland) was intravenously injected. Epidepride peaks at about 25 min after bolus injection in temporal cortical areas 8 and thus SPET scan was started 30 min and completed 60 min after injection of tracer using a dedicated MultiSPECT 3 gamma camera with fanbeam collimators (Siemens Medical Systems Inc., Hoffman Estates, IL, USA). The imaging resolution was 9-10 mm and the imaging protocol is previously described. 5 Transaxial slices (6 mm thick) were reconstructed and corrected for attenuation. Three contiguous transaxial slices (total thickness of 18 mm) were used for the region of interest analysis at the level of temporal pole (see Figure 1) and at the level of cerebellum. Regions of interest were drawn blindly (without knowing whether the subject was a patient or a control subject) onto the cerebellum (as a reference region ¼ free þ non-specific binding) and the temporal pole ( ¼ free þ nonspecific þ specific binding). Specific binding of [
123 I]epidepride in the temporal pole was calculated from the average count density of each region as (temporalÀcerebellum)/ cerebellum. Cerebellum can be used as a reference region because of the fact that the cerebellar count density did not significantly differ between patients (mean: 1470 counts/cm 3 of the tissue) and controls (1550 counts/cm 3 of the tissue, respectively). The intraclass correlation coefficients calculated on the basis of two repeated determinations (in temporal pole) in 11 subjects (six patients and five controls) were 0.85 on the left and 0.95 on the right. The anterior cingulate cortex was excluded from further analysis, since the specific binding values were too low, resulting in low intraclass correlation coefficient (0.4). When the frontal cortex was measured as a whole, the specific binding values were even lower than that for the anterior cingulate cortex. T2-weighted magnetic resonance imaging of the brain was performed using a 1.5 T scanner (Siemens Magnetom, Siemens Medical Systems Inc., Erlangen, Germany).
We used the one-way ANCOVA with age as the covariate to compare the differences in D 2 receptor binding between patients with schizophrenia and healthy controls. Age was the covariate since recent PET studies with high-affinity radioligand [ 11 C]FLB 457 have indicated age-related decrease in D 2/3 receptor densities 9-12% per decade in the temporal cortex. 9, 10 Relation between the temporal D 2/3 densities adjusted for age and the different dimensions of PANSS scores of the patients were assessed using regression analysis and Pearson's two-tailed correla- 
